<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="216">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02335918</url>
  </required_header>
  <id_info>
    <org_study_id>CDX1127-02</org_study_id>
    <nct_id>NCT02335918</nct_id>
  </id_info>
  <brief_title>A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors</brief_title>
  <official_title>A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celldex Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Celldex Therapeutics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to determine the clinical benefit (how well the drug works), safety, and
      tolerability of combining varlilumab and nivolumab (also known as BMS-936558). Both drugs
      target the immune system and may act to promote anti-cancer effects. The study will enroll
      patients with the following cancer types: Non-Small Cell Lung Cancer, Melanoma, Colorectal,
      Ovarian or Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma and Glioblastoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Varlilumab is a fully human monoclonal antibody that binds to a molecule called CD27 found
      on certain immune cells and may act to promote anti-tumor effects.

      Nivolumab is a full human monoclonal antibody that binds to a molecule called PD-1 on immune
      cells and promotes anti-tumor effects.

      This study will evaluate the safety, tolerability and efficacy of anti-CD27 antibody
      varlilumab in combination with anti-PD-1 antibody nivolumab.

      Eligible patients that enroll in the dose escalation portion of the study will be assigned
      to one of three dose levels of varlilumab in combination with 3 mg/kg of nivolumab. The
      first phase of the study will test the safety profile of the combination and determine which
      dose will be studied in Phase ll of the overall study.

      During Phase ll, six cohorts of 18-35 patients each (dependent on cancer type) will be
      enrolled and receive 3 mg/kg of varlilumab in combination with nivolumab at 240 mg.

      All patients enrolled in the study will be closely monitored to determine if there is
      response to the treatment as well as for any side effects that may occur.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Phase I: Number of participants with treatment-related adverse events as determined by CTCAE v4.0, dose-limiting toxicities, and laboratory abnormalities in patients being treated with the combination of varlilumab and nivolumab.</measure>
    <time_frame>Safety follow-up is 100 days from last study drug dose.</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Preliminary antitumor activity of the combination of varlilumab and nivolumab as measured by objective response rate (ORR) in patients with NSCLC, CRC, ovarian cancer, RCC and SCCHN and Overall Survival-12 months (OS12) in patients with GBM.</measure>
    <time_frame>Safety follow-up is 100 days from last study drug dose.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Non-small Cell Lung Cancer (NSCLC)</condition>
  <condition>Squamous Cell Carcinoma of the Head and Neck (SCCHN)</condition>
  <condition>Ovarian Carcinoma</condition>
  <condition>Colorectal Cancer (CRC)</condition>
  <condition>Renal Cell Carcinoma (RCC) (Phase ll Only)</condition>
  <condition>Glioblastoma (GBM) (Phase ll Only)</condition>
  <condition>Melanoma (Phase 1 Only)</condition>
  <arm_group>
    <arm_group_label>Varlilumab and Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination of varlilumab and nivolumab</intervention_name>
    <description>During the treatment phase of the study, eligible patients will receive varlilumab for 3 cycles, with an option for a 4th cycle as determined by study doctors. Treatment cycles are eight weeks each with study drug administered once every two weeks. There is no limit on the number of cycles of nivolumab. Patients may be discontinued from receiving study treatment (nivolumab or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.
Phase I Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.1 mg/kg, 1 mg/kg, or 10 mg/kg.
Phase II Dose: Patients enrolled in the Phase ll study phase will receive 3.0 mg/kg of varlilumab in combination with nivolumab at 240 mg every 2 weeks.</description>
    <arm_group_label>Varlilumab and Nivolumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Histologically-diagnosed advanced (unresectable and/or metastatic) Non-small Cell
             Lung Cancer, Melanoma, Colorectal, Head and Neck SCC (squamous cell carcinoma),
             Ovarian Cancer, Glioblastoma or Renal Cell Carcinoma.

               -  1a. Head and Neck

             Stage III/IV squamous cell carcinoma; Tumor progression or recurrence within 6 months
             of last dose of platinum therapy in the adjuvant, primary, recurrent or metastatic
             setting. Active brain metastases or leptomeningeal metastases are excluded; confirmed
             recurrent or metastatic carcinoma of the nasopharynx and salivary gland or
             non-squamous histologies are also excluded.

               -  1b. Ovarian

             Recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal
             carcinoma requiring original or subsequent relapse histologic documentation. A
             platinum-taxane based chemotherapy regimen as frontline therapy must have been
             completed.

             Any histologic diagnosis of borderline, low malignant potential epithelial carcinoma
             are excluded.

               -  1c. Non-Small Cell Lung Cancer

             Refractory or recurrent histologically or cytologically confirmed; unresectable;
             non-squamous NSCLC must have been tested for EGFR mutation and ALK translocation and
             if positive should have received appropriate tyrosine kinase inhibitor therapy prior
             to enrollment; non-squamous histology, squamous adenosquamous histology, or NSCLC NOS
             histology after completion of treatment with at least 4 cycles of platinum doublet
             chemotherapy with or without bevacizumab.

               -  1d. Colorectal Cancer

             Metastatic or recurrent; prior treatment progression during, after, or intolerant
             following the last administration of approved standard therapies (required therapies
             apply).

               -  1e. Glioblastoma

             Have histologically confirmed World Health Organization Grade IV malignant glioma
             (glioblastoma).

               -  Previous first line therapy with at least radiotherapy and temozolomide.

               -  Participants must have shown unequivocal evidence of tumor progression.

               -  More than one relapse, secondary glioblastoma and prior treatment with
                  bevacizumab are excluded.

             An interval of at least 12 weeks from the completion of radiation therapy to start of
             study treatment.

               -  1f. Renal Cell Carcinoma

             Have histologically confirmed diagnosis of predominant clear cell renal cell
             carcinoma.

               -  Must have received 1 or 2 prior anti-angiogenic therapies.

               -  No more than 5 total previous regimens of systemic therapy, including cytokines
                  and cytotoxic chemotherapy.

               -  Disease progression during or after the last treatment regimen and within 6
                  months before study entry.

          2. No more than 5 prior anticancer regimens for advanced (recurrent, locally advanced or
             metastatic) disease except for patients with GBM which must have first recurrence of
             GBM by diagnostic biopsy or contrast enhanced magnetic resonance imaging (MRI).

          3. Measurable (target) disease.

          4. Life expectancy â‰¥ 12 weeks.

          5. If of childbearing potential (male or female), agree to practice an effective form of
             contraception during study treatment and for at least 23-31 weeks following last
             treatment dose.

        Key Exclusion Criteria:

          1. History of severe hypersensitivity reactions to other monoclonal antibodies.

          2. Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 antibody.

          3. Receipt of anti-CTLA-4 or anti-CD27 antibody within 3 months prior to the planned
             start of study treatment.

          4. Use of any monoclonal based therapies within 2-4 weeks prior to the first dose of
             study treatment.

          5. Chemotherapy within 21 days or at least 5 half-lives (whichever is shorter) prior to
             the planned start of study treatment.

          6. BRAF/MEK inhibitors within 2 weeks prior to the first dose of study treatment.

          7. Systemic radiation therapy within 4 weeks, prior focal radiotherapy within 2 weeks,
             or radiopharmaceuticals (strontium, samarium) within 8 weeks prior to the first dose
             of study treatment.

          8. Use of immunosuppressive medications within 4 weeks or systemic corticosteroids
             within 2 weeks prior to first dose of study treatment.

          9. Other prior malignancy, except for adequately treated basal or squamous cell skin
             cancer or in situ cancers; or any other cancer from which the patient has been
             disease-free for at least 3 years.

         10. Active, untreated central nervous system metastases.

         11. Active autoimmune disease or a documented history of autoimmune disease

         12. Active diverticulitis.

         13. Significant cardiovascular disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Celldex Therapeutics</last_name>
    <email>info@celldex.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Stanford Center for Clinical and Translational Education and Research</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Branimir Sikic, MD</last_name>
      <phone>650-725-6427</phone>
      <email>brandy@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Branimir Sikic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Smillow Cancer Hospital at Yale University Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Madura</last_name>
      <phone>203-737-5381</phone>
      <email>matthew.madura@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amanda Ralabate, RN</last_name>
      <phone>203-752-7961</phone>
      <email>amanda.ralabate@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mario Sznol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington, DC</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Macke, RN</last_name>
      <email>LAB228@georgetown.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Ley, RN</last_name>
      <email>LeyL@georgetown.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Pishvaian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Lutzky, MD</last_name>
      <email>jose.lutzky@msmc.com</email>
    </contact>
    <investigator>
      <last_name>Jose Lutzky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meghan Wyse, PhD</last_name>
      <email>wysem@karmanos.org</email>
    </contact>
    <contact_backup>
      <last_name>Clarice Zuccaro</last_name>
      <email>zuccaroc@karmanos.org</email>
    </contact_backup>
    <investigator>
      <last_name>Amy Weise, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristian Baquero</last_name>
      <phone>212-305-3432</phone>
      <email>cb3180@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Naiyer Rizvi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Callahan, MD, PhD</last_name>
      <phone>646-888-3359</phone>
    </contact>
    <investigator>
      <last_name>Margaret Callahan, MD, PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Health &amp; Services</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara Foote, RN BSN OCN</last_name>
      <email>tara.foote@providence.org</email>
    </contact>
    <contact_backup>
      <last_name>Kim Sutcliffe, RN</last_name>
      <email>Kim.sutcliffe@providence.org</email>
    </contact_backup>
    <investigator>
      <last_name>Rachel Sanborn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 15, 2016</lastchanged_date>
  <firstreceived_date>December 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opdivo</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
